Q-omics provides the consensus-scored NKX1-2 profile across patient tissues and cancer cell-line models. NKX1-2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, NKX1-2 is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, NKX1-2 RNA expression shows 10,609 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight COAD, LUAD, and ESCA as cancer lineages where NKX1-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NKX1-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NKX1-2 survival associations across molecular data types. NKX1-2 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NKX1-2 RNA expression–survival associations across cancer types. High NKX1-2 expression shows unfavorable associations in COAD, UCEC, UVM and SKCM, but favorable associations in CESC and LGG. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify COAD as the clearest survival context for NKX1-2 RNA expression.
This table summarizes NKX1-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for NKX1-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NKX1-2 shows lower tumor expression in BRCA and KIRP and higher tumor expression in LUAD, LUSC, UCEC and BLCA. The LUAD box plot shows higher NKX1-2 RNA expression in tumor versus normal tissue (log2 FC = +1.061, t-test p < 0.001).
This table shows molecular features associated with NKX1-2 in patient tissues and cancer cell lines. In patient samples, NKX1-2 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, NKX1-2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and URINARY_TRACT.
